According to the last available data from the World Health Organization*, in 2012 there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer worldwide, making it one of the most impacting and challenging diseases of modern times. The pharmaceutical industry is actively targeting multiple aspects of oncology and there is an increasing need of compounds that can affect multiple processes at the same time.

We are developing three products for the treatment of several types of cancer: 4P005, a NCE displaying high cytotoxic properties against tumor cells, 4P 009 a peptide for which we are currently establishing a proof-of-concept and proof-of-mechanism, and 4P012 a fixed dose combination product.

Preliminary efficacy studies on models for pancreatic cancer and melanoma have highlighted their potential as novel anti-tumour therapies. Both compounds have showed a good bioavailability and no apparent toxicity in preclinical studies so far.

pipeline_oncology_4P-Pharma

*Source: http://globocan.iarc.fr